-
CM Mohan Yadav Meets Bohra Spiritual Leader to Discuss Simhastha 2028 and Development
-
Mahayuti-backed Rajesh Patil Elected Chairman of Gokul Dairy Amidst Political Deadlock
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
T4 Robotics Appoints Paul Hughes as Co-CEO and Announces Expansion into Unmanned Maritime Systems
-
ClearSign Receives Order for "M1" Series Burner from Tulsa Heaters Midstream (THM)
-
Kalm with Kava and Pū'iwa Farms Hawai'i Bring Fresh Frozen Hawaiian Kava to Market
-
Innovative Menopause Medicine from JASTLabs Advances Patent Protection Internationally
-
SMX Advances Development of its Scientific Intelligence, an AI-Powered Platform Intended to Create a Comprehensive Codex for Chemical Agents, Additives and Supplements
-
Jerash Holdings Reports Fiscal 2027 Second Quarter Financial Results
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
SNZweig Forms AEC Industry Advisory Council
-
Greene Concepts Highlights Groundwater Resources and Commercial Opportunities
-
Wash100 Award, GovCon Industry's Highest Honor, Opens Nominations for 2027 Season
-
Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units
-
Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
-
INEO Invited to 15th Annual ROTH Technology Conference in New York
-
Moderna to Present at Upcoming Conference in November 2026
-
Electrovaya to Participate in Upcoming Investor Conferences
-
Aston Bay Announces Pre-Feasibility Study Results and Maiden Mineral Reserve for the Storm Copper Project, Nunavut
-
Aztec Drills 70.1 Meters of 0.80 g/t AuEq (0.49 g/t Au and 16.85 g/t Ag) from Surface in TR26-54 at the Tombstone Project, Arizona
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show
Exousia Pro has a 60% margin built-in on each order of exosomes
ORLANDO, FLORIDA / ACCESS Newswire / April 8, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to announce that it has received an order to deliver 500 billion dried exosomes.
The order of 500 billion exosomes will be mixed into a cream and packaged into 100 samples containing 5 Billion Exosomes each. This will allow the marketing team to showcase a new product using exosomes. They will further demonstrate that exosomes do not alter the feel or consistency of their existing product, which is currently sold at large box stores nationwide. The marketing team will write orders at and after the show, and we anticipate larger orders to follow.
Exousia Pro is working with a company that services over 300 clients, including MedSpas and Dermatologist offices. They currently use mammalian exosomes but want to switch to plant-based to expand their sales channels for those who will not use mammalian for religious or ethical reasons. They sell 1,500 bottles of hair serum per month and plan to switch to plant-based exosomes, expanding their monthly sales volume and product line to feature new products using our mushroom exosomes.
An order of 5 billion exosomes would currently sell for $5.00, and they cost $2.00 per 5 billion to manufacture. Exousia Pro plans to build on this relationship and expand to other worldwide sales channels that offer similar products. Our prices will increase as we begin to gain market share.
This order will showcase a significant feature Exousia Pro can offer: the ability to supply dried exosomes. By drying the exosomes, we can increase their shelf life. We believe Exousia Pro is the only Company currently able to produce and supply dried plant-based exosomes, which have many applications in the medical and cosmeceuticals markets.
Matt Dwyer, our President, stated, "Exousia Pro's primary focus is using its exosomes to create new treatments for the world's deadliest cancers. While this process is enriching, it can take time to achieve. During this time, we can use other sales channels to bring in revenue that will allow us to keep our focus on developing these new cancer treatments. We have several new sales channels we will be revealing soon. Using the feedback we receive from these early orders, along with testimonials and pictures, will make our entry into other markets much easier. Currently, no plant-based exosomes are being used in topical treatments, so we are first to market."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
[email protected]
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
S.F.Warren--AMWN